Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 2838497A

Next Previous
Drug Profile

GSK 2838497A

Alternative Names: GSK 2231395A; GSK 2254232A; GSK 2254233A; GSK 2838500A; GSK 2838501A; GSK 2838502A; GSK 2838503A; GSK 2838504A; GSK 2838505A; GSK 2838506A; GSK 2838507A; GSK 2838508A; GSK2838497A; Non-typeable Haemophilus influenzae (NTHi) vaccine - GSK; Non-typeable Haemophilus influenzae/pneumococcal adult vaccine - GSK; NTHi-10-AS01E; NTHi-Pneumo

Latest Information Update: 28 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Haemophilus vaccines; Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Haemophilus infections; Pneumococcal infections

Most Recent Events

  • 27 Aug 2019 No development reported - Phase-II for Haemophilus infections (In the elderly, Prevention, In adults) in Sweden, United Kingdom (IM) (NCT02075541)
  • 19 Apr 2017 GlaxoSmithKline completes the phase II NTHI 004 trial for Haemophilus infections (Prevention, In adults and the elderly with COPD) in United Kingdom and Sweden (NCT02075541)
  • 01 Jul 2014 Phase-II clinical trials in Haemophilus infections (Prevention, In adults and the elderly with COPD) in United Kingdom (IM)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top